Launched at an event in the European Parliament today, the ACHIEVE (short for Associations Collaborating on Hepatitis to Immunize and Eliminate the Viruses in Europe) coalition calls on the EU to take action to eliminate viral hepatitis B and C by 2030 in the WHO European Region, in line with the WHO Global Health Sector Strategy on viral hepatitis, the WHO Europe Action Plan, which build on and the UN Sustainable Development Goals (SDGs). On the occasion of the 1st EU NAFLD – NASH Policy Summit, organized by ELPA on May 31st 2107, Commissioner Carlos Moedas sent a video message on the importance of research and innovation in fighting this disease. Aiming to point out to a still missing and much needed concrete action across Europe to face the next major public health challenge, NAFLD and NASH, leading European and national policy-makers, decision-makers, experts, medical specialists and patient advocacy groups active in liver diseases, met at the first European-wide NAFLD-NASH Policy Summit. ELPA and Norgine have launched a patient leaflet to improve the early detection of hepatic encephalopathy, and a patient passport to facilitate conversations with healthcare professionals. Hepatic encephalopathy remains under-diagnosed and under-treated, as many patients and carers are unaware of the signs and symptoms of the disease. In addition, healthcare providers don’t always identify and treat the often subtle symptoms of hepatic encephalopathy, and this can lead to poor patient outcomes and increased hospital admissions.1 Hepatic encephalopathy is a significant complication of advanced chronic liver disease, and occurs in up to 40% of patients or as many as 200,000* people in Europe. 1,2 What is Next for the Liver? European Liver Patients’ Association released the 2016 Hep-CORE Report on the state of viral hepatitis policy and practice in Europe in Berlin on December 20th. This report, conducted under the direction of Prof. Jeffrey V. Lazarus of ISGlobal, University of Barcelona, reveals the sobering results showing that fifty-two per cent (52%) of surveyed European (25) and Mediterranean Basin (2) countries lack national strategies to address viral hepatitis B or C, despite the WHO World Health Assembly resolution calling on all countries to have one. Only three of these countries have access to the new, highly effective medicines (directacting antivirals) for hepatitis C without restrictions. Results will provide doctors and cancer researchers with insights to improve liver cancer treatment now, and in the future ELPA presents the stark findings of the 2016 Hep-CORE Report Presentation of the 27-country Hep-CORE 2016 study results We, the European Liver Patients Association representing patients with liver disease in Europe, would like to draw attention to the urgent public health problem of access to the latest medical therapies for the treatment of patients with hepatitis C. BRUSSELS, BELGIUM, 26 JULY 2016 – The European Liver Patients Association (ELPA), in collaboration with a European research team, recently launched the Hep-CORE study to assess national responses to viral hepatitis in the region, collecting a preliminary dataset in advance of World Hepatitis Day (28 July 2016). The data, which were obtained by surveying ELPA member groups, suggest that some European countries are falling short in terms of the policies and practices that public health experts and the World Health Organization recommend as the basis for an effective response to the hepatitis B virus (HBV) and hepatitis C virus (HCV) epidemics. Dear visitors, look for our article on the page 82 of the Brussels Airlines inflight magazine. The ELPA President has participated 69 World Health Assembly in Geneve where the adoption of the first ever Global Hepatitis Strategy took place on 28th of May at exactly 12:35 p.m. ELPA members had participated in various lectures, workshops and symposia at the International Liver Congress (ILCTM ) during the 51st annual meeting of the European Association for the Study of the Liver (EASL), held in Barcelona 13th – 17th April 2016. « New Hepatitis C antivirals: Is universal access still a dream? » Meeting between the European Commissioner for Health, Vytenis Andriukaitis, and Tatjana Reic and Ivan Gardini, President and Vice President of ELPA, on 11 January in Brussels, to discuss future EU policies with regard to hepatitis C and alcohol. The Commissioner recognises the opportunity to eliminate HCV and discussed possible opportunities within the limits of EU competence, respecting the subsidiarity principle. ELPA, together with other leading NGOs in the field of public health, issued an open letter to Members of the European Parliament, urging them to put public health at the forefront of the EU Alcohol Strategy Resolution.